A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Josep M. Llovet, Karen Shepard, RS Finn, Masafumi Ikeda, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, H. Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Kalgi Mody, Tomoki Kubota, Kenichi Saito, A.B. Siegel, Leonid Dubrovsky, Andrew X. Zhu (2019). A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results. Annals of Oncology, 30, pp. v286-v287, DOI: 10.1093/annonc/mdz247.073.
